STOCK TITAN
  1. Home
  2. News
  3. FATE

Fate Therapeutics, Inc. - FATE STOCK NEWS

Welcome to our dedicated page for Fate Therapeutics news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutics stock.

Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's innovative approach leverages induced pluripotent stem cell (iPSC) technology to create off-the-shelf, engineered NK- and T-cell product candidates designed to deliver multiple therapeutic mechanisms to patients.

Fate Therapeutics' proprietary iPSC product platform enables the mass production of multiplexed-engineered cell products that are uniform in composition and can be stored for off-the-shelf availability. This platform allows for the efficient manufacture of well-defined cell therapies that can be used in combination with other treatments, significantly overcoming the limitations of patient- or donor-sourced cells.

Recent highlights include the initiation of patient enrollment in the Phase 1 study of FT522, an ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma. Additionally, the FDA has cleared the IND application for FT825/ONO-8250 in solid tumors, marking a key milestone in the company's collaboration with ONO Pharmaceutical. The expansion of the iPSC product platform into autoimmunity with FT819, targeting systemic lupus erythematosus, further underscores Fate Therapeutics' commitment to addressing complex diseases.

The company's financial health remains robust, bolstered by recent funding efforts, including the sale of shares and pre-funded warrants to institutional investors. Fate Therapeutics continues to lead in the field of cellular immunotherapies, with a strong pipeline of product candidates and an intellectual property portfolio comprising over 500 issued patents and 500 pending patent applications.

Headquartered in San Diego, CA, Fate Therapeutics is dedicated to advancing its clinical programs and providing innovative treatments to improve patient outcomes. For more information, please visit www.fatetherapeutics.com.

News

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Fate Therapeutics, Inc. (FATE) granted restricted stock units (RSUs) representing 32,600 shares of its common stock to two newly-hired non-executive employees. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
management
-
News

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

Rhea-AI Summary
Fate Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: FATE), has initiated enrollment for its Phase 1 clinical trial of FT825 / ONO-8250, a multiplexed-engineered, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2). The company's iPSC-derived CAR T-cell product candidate incorporates a novel HER2-targeted antigen binding domain and is designed to treat solid tumors. The Phase 1 study is being conducted in collaboration with Ono Pharmaceutical Co., Ltd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.28%
Tags
clinical trial
-
News

Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO

Rhea-AI Summary
Radionetics Oncology, Inc. (RADN) completes $52.5 million Series A financing led by Frazier Life Sciences, 5AM Ventures, and DCVC Bio, bringing total raised to date to $82.5 million. Paul Grayson joins as CEO, bringing expertise in business strategy, oncology, and G-protein coupled receptor biology. Eric Shiozaki, Ph.D., Partner at DCVC Bio, appointed to the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
management
News

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Fate Therapeutics, Inc. (NASDAQ: FATE) granted a non-qualified stock option to a newly-hired employee to purchase 350,000 shares at an exercise price of $2.28 per share. The option vests over four years, subject to the employee's continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.19%
Tags
management
-
News

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Rhea-AI Summary
Fate Therapeutics, Inc. (NASDAQ: FATE) reports progress in their iPSC-derived cellular immunotherapies for cancer and autoimmune disorders. Key highlights include the initiation of a Phase 1 study for FT522 ADR-armed, CD19-targeted CAR NK cell program, clearance of IND application for FT825/ONO-8250 CAR T-cell program for solid tumors, and expansion of the iPSC product platform into autoimmunity with FT819 CD19-targeted 1XX CAR T-cell program for systemic lupus erythematosus. The company also reported $350 million in cash, cash equivalents, and investments to support operations into 2H25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.58%
Tags
earnings
-
News

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Rhea-AI Summary
Fate Therapeutics to report Q3 2023 financial results and provide corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
conferences earnings
News

Fate Therapeutics to Present at Upcoming September Investor Conferences

Rhea-AI Summary
Fate Therapeutics announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
conferences
-
News

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Rhea-AI Summary
Fate Therapeutics, Inc. (NASDAQ: FATE) reported business highlights and financial results for the second quarter ended June 30, 2023. The company has shown resilience in advancing its innovative programs while reducing expenses, ending 2Q23 with $385 million in cash, cash equivalents, and investments, supporting a runway into 2H25. It has commenced Phase 1 study start-up for FT522 ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma and initiated GMP manufacturing of FT825/ONO-8250 under the solid tumor collaboration with ONO Pharmaceutical. The company's FT819 program is advancing in single-dose escalation cohorts for B-cell malignancies, and a 2H23 IND submission is planned for the HER2-targeted CAR T-cell program for solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
earnings
-
News

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Rhea-AI Summary
Fate Therapeutics, Inc. (FATE) to Report Q2 2023 Financial Results and Corporate Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences earnings
News

Fate Therapeutics to Present at Upcoming June Investor Conferences

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
conferences

FAQ

What is the current stock price of Fate Therapeutics (FATE)?

The current stock price of Fate Therapeutics (FATE) is $1.66 as of December 24, 2024.

What is the market cap of Fate Therapeutics (FATE)?

The market cap of Fate Therapeutics (FATE) is approximately 189.1M.

What does Fate Therapeutics specialize in?

Fate Therapeutics specializes in the development of programmed cellular immunotherapies for cancer and autoimmune disorders using induced pluripotent stem cell (iPSC) technology.

What is the iPSC product platform?

The iPSC product platform is a proprietary technology that allows Fate Therapeutics to mass-produce multiplexed-engineered cell products that are uniform in composition and can be stored for off-the-shelf availability.

What are the recent achievements of Fate Therapeutics?

Recent achievements include the initiation of Phase 1 studies for FT522 in B-cell lymphoma and the FDA clearance of the IND application for FT825/ONO-8250 in solid tumors. The company also expanded its iPSC platform into autoimmunity with FT819 for systemic lupus erythematosus.

What is the financial condition of Fate Therapeutics?

Fate Therapeutics is financially robust, supported by recent funding through the sale of shares and pre-funded warrants to institutional investors, which are expected to generate approximately $100 million in gross proceeds.

Where is Fate Therapeutics headquartered?

Fate Therapeutics is headquartered in San Diego, California.

How does Fate Therapeutics address the limitations of patient- or donor-sourced cells?

Fate Therapeutics uses its iPSC product platform to produce well-defined, uniform cell therapies that can be stored off-the-shelf, overcoming the limitations associated with patient- or donor-sourced cells.

What is the significance of FT522 and FT825/ONO-8250?

FT522 is an ADR-armed, CD19-targeted CAR NK cell program for B-cell lymphoma, and FT825/ONO-8250 is an iPSC-derived CAR T-cell program for solid tumors. Both represent significant advancements in Fate Therapeutics' clinical pipeline.

What diseases does Fate Therapeutics aim to treat?

Fate Therapeutics develops treatments for a range of diseases, including cancer, autoimmune disorders, hematological diseases, traumatic injuries, and degenerative diseases.

What makes Fate Therapeutics' iPSC product platform unique?

The iPSC product platform is unique due to its ability to mass-produce multiplexed-engineered cell products that are well-defined, uniform, and can be stored for off-the-shelf availability, making them readily accessible for patients.

How can I learn more about Fate Therapeutics?

For more information, you can visit Fate Therapeutics' official website at www.fatetherapeutics.com.

Stock FATE logo
Fate Therapeutics, Inc.

Nasdaq:FATE

FATE Rankings

#3932 Ranked by Market Cap
N/A Ranked by Dividends

FATE Stock Data

189.06M
109.39M
2.17%
102.7%
9.12%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO